Regarding taxes reducing gross profits, at least for the first few years that won't happen due to the loss carry forwards that VRTX has accumulated so far (up to $1.9 B as of last september, and I figure another $1.5+ more till TVA is marketed) which offsets that much of the profits until it is all used up.
Glad, very true.. you are right. But there would be a large difference between the actual revenue per treatment vs. the cost of the drug per treatment because whole sale price would be much less than the amount each patient pays, and because there would be compassionate distribution of the drug to those who cannot afford it particularly when the treatment cost is as high as $35K. I have used a very conservative figure for P/E, and also assumed that the share number will be 300 million almost twice of the current outstanding shares (I am sure that VRTX will acquire one or more biotech companies using its shares on the contrary to general expectations). Boger's visibility is gone, but his ambition to make VRTX into a major pharma is not (he will be an active Board member as PR stated).